Background {#s1}
==========

Precision medicine is an emerging approach for providing patient-specific treatment based on genomic data using next generation sequencing (NGS). Reliable and accurate NGS technologies are essential in precision medicine ([@B1]). Several commercial genomic tests are available ([Table 1](#T1){ref-type="table"}). Each of these tests has different characteristics including the sequencing system; the number of tested genes; sample type such as tumor, blood, or paired specimens; and the curation and annotation system.

###### 

Comparison of the genomic tests NCC-Oncopanel®, MSK-IMPACT®, Guardant360®, and FoundationOne CDx®.

  **Platform**                 **Target**    **Sample type**                    **Genes tested**             **Turnaround time**   **Approval**
  ---------------------------- ------------- ---------------------------------- ---------------------------- --------------------- ------------------------
  NCC-Oncopanel® ([@B2])       Solid tumor   Tumor (FFPE) and blood (control)   114 genes                    --                    Japan-approved
  MSK-IMPACT® ([@B3])          Solid tumor   Tumor (FFPE) and blood (control)   468 genes                    21 days               FDA-approved
  Guardant360® ([@B4])         Solid tumor   Blood (cfDNA)                      73 genes (Point mutations)   7 days                --
  FoundationOne CDx® ([@B5])   Solid tumor   Tumor (FFPE)                       324 genes                    Within 14 days        FDA and Japan-approved

*FFPE, formalin fixation and paraffin embedding; cfDNA, cell-free DNA*.

Clonal hematopoiesis (CH) produces a detectable somatic clonal mutation that is commonly associated with clonal expansion of hematopoietic cells with age ([@B6]). As the use of NGS analysis has increased, studies have reported some discordances between genotyping results from tumor tissue and plasma specimens, which may be caused by tumor heterogeneity, variable shedding of tumor DNA into the plasma, and/or CH ([@B7], [@B8]). Here, we report a case of *TP53*-mutated CH in a patient with lung adenocarcinoma.

Case Presentation {#s2}
=================

A 74-year-old Korean man was referred to us for lung adenocarcinoma with left scapula metastasis. He had a normal complete blood count and no family history of malignant disease. Following palliative radiotherapy to the scapula, he had been treated with multi-line chemotherapies. However, his scapula metastasis had progressed. He provided written informed consent to undergo genomic testing. Undecalcified tumor tissue of the scapula metastasis from lung adenocarcinoma and a blood sample were submitted for NGS genomic testing using NCC-Oncopanel test, which was developed at the National Cancer Center in Japan. Testing of the blood sample detected a *TP53* mutation (C135Y c404G\>A \[p.Cys135Tyr\], allele frequency 29.8%), but there was no matching mutation in the tumor tissue ([Figure 1](#F1){ref-type="fig"}). The criteria for myelodysplastic syndromes (MDS), Waldenström macroglobulinemia, IgM monoclonal gammopathy of undetermined significance (IgM-MGUS), and Li-Fraumeni syndrome were not met. We suspected CH as the cause of the discordance between findings in tumor tissue and blood. We therefore verified the presence of the *TP53* mutation with a *TP53* target sequencing test using the sequencing by synthesis method (Falco Holdings Co., Ltd.) in blood and normal oral mucosa. The *TP53* mutation C135Y was only detected in the blood ([Table 2](#T2){ref-type="table"}).

![The data of patient\'s sample using next generation sequencing visualized by Integrative Genome Viewer ([@B9]). **(A)** Testing of the peripheral blood sample detected a *TP53* mutation (C135Y c404G\>A \[p.Cys135Tyr\], allele frequency 29.8%). **(B)** Testing of the tumor tissue showed no *TP53* mutation.](fonc-10-00113-g0001){#F1}

###### 

Results of genomic tests in a patient with *TP53*-mutated CH.

  **Testing**   **Sample**          **Fresh or archived**   **Mutation**                                                **Results**
  ------------- ------------------- ----------------------- ----------------------------------------------------------- -----------------------------------------------------
  1st testing   Tumor Blood         Archived Fresh          No mutation *TP-53* mutation                                Discordance between tumor and blood specimens
  2nd testing   Oral mucosa Blood   Fresh Fresh             No mutation *TP-53* mutation C135Y c404G\>A (p.Cys135Tyr)   Discordance between oral mucosa and blood specimens

*CH, clonal hematopoiesis*.

Discussion and Conclusions {#s3}
==========================

CH is an aging-related phenomenon in which hematopoietic stem cells or other early blood cell progenitors contribute to the formation of a genetically distinct subpopulation of blood cells ([@B6]). CH is considered to be associated with prior exposure to chemotherapy or irradiation in cancer patients as well as increased age ([@B10]). Plasma cell-free DNA genotyping detected that some mutations such as *JAK2, TP53*, and *KRAS* can be derived from CH and not from cancer ([@B7]).

The cause of the genotyping discordance between tumor tissue and blood is important for determining the treatment strategy. Although the *TP53* mutation is not targetable, germline *TP53* mutations result in a hereditary condition known as Li-Fraumeni syndrome and the *KRAS* mutation is a predictive marker of response to cetuximab therapy in colorectal cancer ([@B11], [@B12]). CH detected from cell-free DNA can cause misdiagnosis of the mutation origin and complicate the treatment strategy ([@B7], [@B8]). Pairing of plasma and tumor genomic tests is important, although paired sample testing is expensive.

We report a case of *TP53*-mutated CH in a lung adenocarcinoma patient in which target sequencing was used to confirm mutations derived from CH.
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